Cyclo Therapeutics Inc
NASDAQ:CYTH
Balance Sheet
Balance Sheet Decomposition
Cyclo Therapeutics Inc
Cyclo Therapeutics Inc
Balance Sheet
Cyclo Therapeutics Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2
|
2
|
1
|
1
|
2
|
3
|
13
|
17
|
2
|
9
|
|
| Cash Equivalents |
2
|
2
|
1
|
1
|
2
|
3
|
13
|
17
|
2
|
9
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
3
|
|
| Total Current Assets |
3
|
3
|
2
|
2
|
3
|
4
|
14
|
19
|
4
|
12
|
|
| PP&E Net |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| PP&E Gross |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
5
N/A
|
5
-10%
|
2
-61%
|
2
+12%
|
3
+40%
|
4
+41%
|
14
+245%
|
20
+38%
|
4
-78%
|
13
+214%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
0
|
1
|
2
|
3
|
4
|
4
|
3
|
6
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
| Short-Term Debt |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
1
|
0
|
1
|
2
|
3
|
4
|
4
|
3
|
8
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
1
+9%
|
0
-66%
|
1
+176%
|
2
+105%
|
3
+65%
|
4
+18%
|
4
+3%
|
3
-10%
|
8
+144%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
3
|
5
|
10
|
13
|
18
|
25
|
34
|
48
|
64
|
84
|
|
| Additional Paid In Capital |
7
|
9
|
11
|
14
|
19
|
26
|
45
|
64
|
65
|
89
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
4
N/A
|
4
-14%
|
2
-59%
|
1
-25%
|
1
-14%
|
1
-5%
|
10
+1 012%
|
16
+50%
|
1
-95%
|
5
+552%
|
|
| Total Liabilities & Equity |
5
N/A
|
5
-10%
|
2
-61%
|
2
+12%
|
3
+40%
|
4
+41%
|
14
+245%
|
20
+38%
|
4
-78%
|
13
+214%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
1
|
5
|
8
|
8
|
29
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|